Pacira BioSciences (PCRX) EBIT (2010 - 2026)

Pacira BioSciences' EBIT history runs 17 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• In Q1 2026, EBIT rose 246.83% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $24.1 million (up 128.49% YoY), while the FY2025 annual figure was $19.2 million, up 126.16% from the prior year.
• EBIT was $6.9 million for Q1 2026 at Pacira BioSciences, up from $2.3 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $39.9 million in Q2 2023 to a low of -$139.5 million in Q3 2024.
• Historically, EBIT has averaged $5.9 million across 5 years, with a median of $13.2 million in 2024.
• Biggest YoY gain for EBIT was 527.43% in 2024; the steepest drop was 887.35% in 2024.
• A 5-year view of EBIT shows it stood at -$9.9 million in 2022, then surged by 435.27% to $33.2 million in 2023, then fell by 25.52% to $24.7 million in 2024, then slumped by 90.53% to $2.3 million in 2025, then soared by 194.96% to $6.9 million in 2026.
• The last three EBIT figures came in at $6.9 million (Q1 2026), $2.3 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.